Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Pharming Group NV Profile



Ticker SymbolPHAR

Company namePharming Group NV

IPO dateJul 02, 1998

CEOChouraqui (Fabrice)

Number of employees- -

Security typeDepository Receipt

Fiscal year-end- -

AddressDarwinweg 24

CityLEIDEN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryNetherlands

Postal code2333 CR

Phone31715247400

Websitehttps://www.pharming.com/

Ticker SymbolPHAR

IPO dateJul 02, 1998

CEOChouraqui (Fabrice)

Company Executives of Pharming Group NV



Name

Name/Position

Position

Shareholding

Change

Mr. Ruud van Outersterp

Chief Legal and Compliance Officer, Company Secretary

Ms. Maryana Reurings-Tsiganko

Vice President - Strategy and Operations

Dr. Elaine Sullivan, Ph.D.

Non-Executive Independent Director

Ms. Leverne Marsh

Interim Co-Chief Executive Officer, Chief Commercial Officer

Mr. Kenneth Lynard

Interim Co-Chief Executive Officer, Chief Financial Officer

Ms. Ines Bernal

Chief People Officer

Mr. Fabrice Chouraqui, Pharm.D.

Chief Executive Officer, Executive Director

Dr. Alexander Breidenbach, Ph.D.

Chief Business Officer

Dr. Richard Peters, M.D., Ph.D.

Non-Executive Independent Chairman of the Board

Mr. Stephen (Steve) Toor

Chief Commercial Officer